Spotlight On... Patheon pairs with Grünenthal on abuse-deterrent R&D; Covance sells a U.K. lab; and more...

Patheon signed a deal with German drugmaker Grünenthal to help develop abuse-deterrent formulations of controlled substances. Under the agreement, Patheon will be the preferred development partner in Grünenthal's efforts to use its proprietary technology to craft opioids, depressants and stimulants with reduced abuse potential. Neither side disclosed financial information. More

> Covance sold a U.K. preclinical research site to investment group Shott Trinova. News

> WuXi PharmaTech launched an app called LabNetwork, which allows chemists to search a database of research chemicals and order them. Item

> Boston's inviCRO and Molecular NeuroImaging are merging operations, creating a unified company that offers imaging services to drugmakers. Release

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.